INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 58 filers reported holding INFINITY PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $27,000 | -49.1% | 23,557 | 0.0% | 0.00% | – |
Q4 2021 | $53,000 | -80.1% | 23,557 | -69.7% | 0.00% | -100.0% |
Q3 2021 | $266,000 | +14.2% | 77,785 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $233,000 | -76.5% | 77,785 | -74.7% | 0.00% | -75.0% |
Q1 2021 | $993,000 | +228.8% | 307,533 | +116.0% | 0.01% | +166.7% |
Q4 2020 | $302,000 | -7.1% | 142,354 | -48.7% | 0.00% | 0.0% |
Q3 2020 | $325,000 | +29.5% | 277,550 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $251,000 | +13.1% | 277,550 | +4.9% | 0.00% | 0.0% |
Q1 2020 | $222,000 | +65.7% | 264,549 | +89.7% | 0.00% | +200.0% |
Q4 2019 | $134,000 | -14.1% | 139,453 | -7.7% | 0.00% | -50.0% |
Q3 2019 | $156,000 | -57.0% | 151,136 | -25.0% | 0.00% | -60.0% |
Q2 2019 | $363,000 | +0.6% | 201,438 | +5.0% | 0.01% | 0.0% |
Q1 2019 | $361,000 | +137.5% | 191,927 | +48.6% | 0.01% | +66.7% |
Q4 2018 | $152,000 | -49.2% | 129,127 | +17.0% | 0.00% | -25.0% |
Q3 2018 | $299,000 | -7.1% | 110,354 | -34.6% | 0.00% | -20.0% |
Q2 2018 | $322,000 | -28.3% | 168,727 | -21.1% | 0.01% | -28.6% |
Q1 2018 | $449,000 | +1.4% | 213,827 | -2.1% | 0.01% | -12.5% |
Q4 2017 | $443,000 | +235.6% | 218,427 | +119.5% | 0.01% | +166.7% |
Q3 2017 | $132,000 | -76.3% | 99,527 | -71.9% | 0.00% | -75.0% |
Q2 2017 | $556,000 | -56.0% | 353,891 | -9.6% | 0.01% | -53.8% |
Q1 2017 | $1,265,000 | +271.0% | 391,671 | +55.0% | 0.03% | +271.4% |
Q4 2016 | $341,000 | +2031.2% | 252,771 | +2033.1% | 0.01% | – |
Q2 2016 | $16,000 | -74.2% | 11,850 | 0.0% | 0.00% | -100.0% |
Q1 2016 | $62,000 | -33.3% | 11,850 | 0.0% | 0.00% | -50.0% |
Q4 2015 | $93,000 | -49.7% | 11,850 | -46.0% | 0.00% | -50.0% |
Q3 2015 | $185,000 | -69.9% | 21,950 | -60.8% | 0.00% | -66.7% |
Q2 2015 | $614,000 | -39.4% | 56,050 | -22.7% | 0.01% | -29.4% |
Q1 2015 | $1,013,000 | -55.6% | 72,485 | -46.4% | 0.02% | -56.4% |
Q4 2014 | $2,282,000 | +201.9% | 135,108 | +139.8% | 0.04% | +200.0% |
Q3 2014 | $756,000 | – | 56,350 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |